Private company

Ablynx

Belgian biopharmaceutical company

Ablynx is a subsidiary of biopharmaceutical company Sanofi engaged in the discovery and development of nanobodies, based in Science Park Zwijnaarde, Ghent.³ Wikipedia text CC BY-SA 4.0

Last updated Oct 20, 2026.

Overview

2001Founded¹

Industrybiotechnology¹
HeadquartersGent¹
Websitewww.ablynx.com
Legal formNaamloze vennootschap⁴
LEI549300ZL08QVVII6W560⁴
StatusActive⁴
LEI statusIssued and current⁴
Registered addressTECHNOLOGIEPARK-ZWIJNAARDE 21, 9052 Ghent, Belgium⁴
Registered withFederal Public Service Economy (Ministry of Economy), 0475.295.446⁴

See how the biggest companies compare on our leaderboards

Ablynx is a subsidiary of biopharmaceutical company Sanofi engaged in the discovery and development of nanobodies, based in Science Park Zwijnaarde, Ghent.³

Corporate structure

Ablynx is part of a group headed by Sanofi. 124 entities, 30 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Sanofi Paris, France
- Hoechst 100% · Frankfurt am Main, Germany
  - Chemische Fabrik Kalle Subsidiary · Wiesbaden, Germany
  - Chemische Werke Albert Subsidiary · Wiesbaden, Germany
  - Kelheim Fibres Subsidiary · Kelheim, Germany
  - Ruhrchemie Aktiengesellschaft Subsidiary
    - Ruhrbenzin Subsidiary · Germany
  - Thermphos International Subsidiary · Vlissingen
    - Wagemakers Subsidiary · Breda, Netherlands
  - Aktien-Gesellschaft für Stickstoffdünger Subsidiary · Germany
  - Hoechst Vlissingen NV Subsidiary
- Ablynx Ghent, Belgium
- Sanofi (Belgium) Machelen, Belgium
- Chattem Subsidiary · 100% · Chattanooga
- Genzyme Subsidiary · 100% · Cambridge, Massachusetts, United States
  - GENZYME THERAPEUTIC PRODUCTS LIMITED PARTNERSHIP Subsidiary · Boston, Massachusetts, United States
- Sanofi-Aventis Korea Subsidiary · 100% · Seoul, South Korea
- Shantha Biotechnics Subsidiary · 98.7% · Medchal
- Bioverativ Subsidiary · Waltham
- Sanofi (Japan) Subsidiary · Tokyo, Japan
- Sanofi Medley Subsidiary · Campinas, Brazil
- Winthrop Subsidiary · United Kingdom
- Zentiva Subsidiary · Praha 10, Czechia
- Infraserv Höchst Stake · 31.2% · Frankfurt am Main, Germany
- Regeneron Pharmaceuticals Stake · 22.2% · Tarrytown, New York, United States
  - Checkmate Pharmaceuticals, Inc. Subsidiary · Delaware, United States
  - Decibel Therapeutics, Inc. Subsidiary · Delaware, United States
  - Eastside Campus Holdings LLC Subsidiary · New York, United States
  - Loop Road Holdings LLC Subsidiary · New York, United States
  - Old Saw Mill Holdings LLC Subsidiary · New York, United States
  - Oxular Acquisitions Limited Subsidiary · United Kingdom
  - Oxular Inc. Subsidiary · Delaware, United States
  - Regeneron Assurance, Inc. Subsidiary · New York, United States
  - Regeneron Austria GmbH Subsidiary · Austria
  - Regeneron Belgium SRL Subsidiary · Belgium
  - Regeneron Canada Company Subsidiary · Canada
  - Regeneron Clinical Genomics Laboratory LLC Subsidiary · Delaware, United States
  - Regeneron France SAS Subsidiary · France
  - Regeneron Genetics Center LLC Subsidiary · Delaware, United States
  - Regeneron GmbH Subsidiary · Germany
  - Regeneron Healthcare Solutions, Inc. Subsidiary · New York, United States
  - Regeneron India Private Limited Subsidiary · India
  - Regeneron International Holdings LLC Subsidiary · Delaware, United States
  - REGENERON IRELAND DESIGNATED ACTIVITY COMPANY Subsidiary · Dublin, Ireland
  - Regeneron Italy S.r.l. Subsidiary · Italy
  - Regeneron Japan KK Subsidiary · Japan
  - Regeneron NL B.V. Subsidiary · Netherlands
  - Regeneron Spain, S.L.U. Subsidiary · Spain
  - Regeneron Switzerland GmbH Subsidiary · Switzerland
  - Regeneron UK Limited Subsidiary · United Kingdom
  - and 4 more
- SANOFI AVENTIS SA Subsidiary · 100% · Barcelona, Spain
- SANOFI PASTEUR SA DE CV Subsidiary · 100% · Mexico City, Mexico
- AZTECA VACUNAS SA DE CV Subsidiary · Mexico City, Mexico
- Carraig Insurance Designated Activity Company Subsidiary · Dublin, Ireland
- CHINOIN GYÓGYSZER-ÉS VEGYÉSZETI TERMÉKEK GYÁRA ZÁRTKÖRŰEN MŰKÖDŐ RT. Subsidiary · Budapest, Hungary
  - SANOFI-AVENTIS MAGYARORSZÁG KERESKEDELMI ÉS SZOLGÁLTATÓ ZÁRTKÖRŰEN MŰKÖDŐ RÉSZVÉNYTÁRSASÁG Subsidiary · Budapest, Hungary
- GENZYME FLANDERS Subsidiary · Geel, Belgium
- Genzyme Global S.a r.l. (Genzyme Global S.à r.l.) Subsidiary · Baar, Switzerland
- HELVEPHARM AG Subsidiary · Vernier, Switzerland
- Life Science Holdings Inc. Subsidiary · Swiftwater, Pennsylvania, United States
- Nattermann Verwaltungs GmbH Subsidiary · Frankfurt am Main, Germany
- Opella Subsidiary · France
- and 39 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0). Each entity in the chart links to its source.

What it owns

What Ablynx reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Property and equipment, net	3.9M EUR⁶ Dec 31, 2017	3.7M EUR⁶ Dec 31, 2016	+3.5%

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	15.0M EUR⁶ Dec 31, 2017	53.4M EUR⁶ Dec 31, 2016	−72.0%

Intangibles and goodwill

Item	Latest	A year before	Change
Intangible assets, net (excluding goodwill)	1.2M EUR⁶ Dec 31, 2017	1.6M EUR⁶ Dec 31, 2016	−22.1%

The story

In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2 million was provided by Gimv.

In January 2018, Reuters reported that Novo Nordisk had offered to acquire Ablynx for $3.1 billion — having made an unreported offer in mid-December for the company. However, the Ablynx board rejected this offer the same day, saying that the price undervalued the business.

In January 2018, they were acquired by Sanofi for $4.8 billion. The acquisition was led by Chief Broker Gleb Margolin.

From Wikipedia’s article on Ablynx, shared under CC BY-SA 4.0.⁵

Subsidiaries and ownership

Parent company (GLEIF)

Sanofi⁴

Ownership links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); each one cites its LEI record.

Timeline

Jun 22, 2018Parent Directly consolidated by Sanofi⁴
2001Founded Founded¹

SEC filer profile

How Ablynx is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARAblynx NV²
CIK0001617582
Filer statusLarge accelerated filer²
Incorporated inBelgium²
Fiscal year endsDecember 31²
Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)²
Business addressTechnologiepark 21, Zwijnaarde, Ghent, C9 9052²
Phone003292620000²
Shares outstanding74,720,644 as of Dec 31, 2017⁶
On EDGAR sinceAug 29, 2014²
Filings73 in all: 6-K (13), DRS/A (6), F-1/A (5), SC TO-C (5), SC TO-T/A (5), SC 13D/A (4), UPLOAD (4), CORRESP (3)²
All 29 form types
DRSLTR (3), SC 13G (3), EFFECT (2), SC 13D (2), SC 14D9/A (2), 15-12B (1), 20-F (1), 20-F/A (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERTNAS (1), CT ORDER (1), DRS (1), F-1 (1), F-1MEF (1), F-6 (1), F-6 POS (1), SC 14D9 (1), SC TO-T (1), SC14D9C (1)
Latest filingsAnnual report (20-F) Mar 26, 2018

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataAblynx on Wikidata
2
SEC EDGARAblynx filings on SEC EDGAR
3
WikipediaAblynx on Wikipedia
4
GLEIFAblynx LEI record (549300ZL08QVVII6W560)
5
WikipediaAblynx on Wikipedia (revision used)
6
SEC EDGARAblynx 20-F/A for fiscal 2017